Drugs / SPH7854
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06483373 | May 2024 → Dec 2026 expected | inflammatory bowel disease | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH7854 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06483373 ↗ |
| Route | Oral | “Orally” NCT06483373 ↗ |